Incorporating human exposure information in a weight of evidence approach to inform design of repeated dose animal studies.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 16 08 2021
revised: 23 10 2021
accepted: 27 10 2021
pubmed: 9 11 2021
medline: 20 1 2022
entrez: 8 11 2021
Statut: ppublish

Résumé

Human health risks from chronic exposures to environmental chemicals are typically estimated from potential human exposure estimates and dose-response data obtained from repeated-dose animal toxicity studies. Various criteria are available for selecting the top (highest) dose used in these animal studies. For example, toxicokinetic (TK) and toxicological data provided by shorter-term or dose range finding studies can be evaluated in a weight of evidence approach to provide insight into the dose range that would provide dose-response data that are relevant to human exposures. However, there are concerns that a top dose resulting from the consideration of TK data may be too low compared to other criteria, such as the limit dose or the maximum tolerated dose. In this paper, we address several concerns related to human exposures by discussing 1) the resources and methods available to predict human exposure levels and the associated uncertainty and variability, and 2) the margin between predicted human exposure levels and the dose levels used in repeated-dose animal studies. A series of case studies, ranging from data-rich to data-poor chemicals, are presented to demonstrate that expected human exposures to environmental chemicals are typically orders of magnitude lower than no-observed-adverse-effect levels/lowest-observed-adverse-effect levels (NOAELs/LOAELs) when available (used as conservative surrogates for top doses). The results of these case studies support that a top dose based, in part, on TK data is typically orders of magnitude higher than expected human exposure levels.

Identifiants

pubmed: 34743952
pii: S0273-2300(21)00214-2
doi: 10.1016/j.yrtph.2021.105073
pmc: PMC8767482
mid: NIHMS1767894
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105073

Subventions

Organisme : Intramural EPA
ID : EPA999999
Pays : United States

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Regul Toxicol Pharmacol. 2020 Jul;114:104659
pubmed: 32334038
Crit Rev Toxicol. 2014 Aug;44 Suppl 3:6-16
pubmed: 25070414
Sci Total Environ. 2018 Sep 15;636:901-909
pubmed: 29729507
Environ Sci Technol. 2015 Jun 2;49(11):6760-71
pubmed: 25932772
Sci Data. 2020 Apr 20;7(1):122
pubmed: 32313097
Crit Rev Toxicol. 2017 Apr;47(4):317-341
pubmed: 28266262
J Cheminform. 2016 Nov 4;8:61
pubmed: 27867422
Risk Anal. 2003 Dec;23(6):1297-308
pubmed: 14641902
Environ Int. 2017 Sep;106:105-118
pubmed: 28628784
Environ Sci Technol. 2014 Nov 4;48(21):12750-9
pubmed: 25222184
Sci Data. 2018 Jul 10;5:180125
pubmed: 29989593
Environ Int. 2017 Nov;108:185-194
pubmed: 28865378
Green Chem. 2017;19(4):1063-1074
pubmed: 30505234
Crit Rev Toxicol. 2013 Mar;43(3):185-99
pubmed: 23402215
J Toxicol Environ Health B Crit Rev. 2012;15(1):22-38
pubmed: 22202228
Environ Health Perspect. 2014 Aug;122(8):769-74
pubmed: 24659601
Environ Sci Technol. 2014 Nov 4;48(21):12760-7
pubmed: 25343693
Regul Toxicol Pharmacol. 2021 Dec;127:105070
pubmed: 34718074
Risk Anal. 2002 Jun;22(3):553-78
pubmed: 12088234
Environ Sci Technol. 2007 May 1;41(9):3233-40
pubmed: 17539531
Toxicol In Vitro. 2013 Aug;27(5):1570-7
pubmed: 22771339
J Cheminform. 2017 Nov 28;9(1):61
pubmed: 29185060
Toxicol Sci. 2015 Nov;148(1):121-36
pubmed: 26251325
Toxicol Sci. 2020 Jan 1;173(1):202-225
pubmed: 31532525
Environ Sci Technol. 2019 Jan 15;53(2):719-732
pubmed: 30516957
Toxicol Lett. 2003 Feb 18;138(1-2):9-27
pubmed: 12559690
Risk Anal. 1994 Oct;14(5):707-12
pubmed: 7800861
Sci Total Environ. 2012 Jan 1;414:159-66
pubmed: 22104386
Environ Sci Technol. 2018 Mar 6;52(5):3125-3135
pubmed: 29405058
Toxicol Sci. 2012 Jan;125(1):157-74
pubmed: 21948869
J Chem Inf Model. 2020 Mar 23;60(3):1215-1223
pubmed: 32073844
Int J Environ Res Public Health. 2016 Jul 22;13(5):
pubmed: 27455300
J Stat Softw. 2017 Jul 17;79(4):1-26
pubmed: 30220889
Environ Sci Technol. 2017 Sep 19;51(18):10786-10796
pubmed: 28809115
Regul Toxicol Pharmacol. 1996 Oct;24(2 Pt 1):108-20
pubmed: 8933624

Auteurs

Kelly Lowe (K)

U.S. Environmental Protection Agency, Office of Pesticide Programs, Washington, DC, USA.

Jeffrey Dawson (J)

U.S. Environmental Protection Agency, Office of Chemical Safety and Pollution Prevention, Washington, DC, USA.

Katherine Phillips (K)

U.S. Environmental Protection Agency, Office of Research & Development, Durham, NC, USA.

Jeffrey Minucci (J)

U.S. Environmental Protection Agency, Office of Research & Development, Durham, NC, USA.

John F Wambaugh (JF)

U.S. Environmental Protection Agency, Office of Research & Development, Durham, NC, USA.

Hua Qian (H)

ExxonMobil Biomedical Sciences, Inc., Annandale, NJ, USA.

Tharacad Ramanarayanan (T)

Syngenta Ltd., Greensboro, NC, USA.

Peter Egeghy (P)

U.S. Environmental Protection Agency, Office of Research & Development, Durham, NC, USA.

Brandall Ingle (B)

U.S. Environmental Protection Agency, Office of Pesticide Program, Durham, NC, USA.

Rachel Brunner (R)

U.S. Environmental Protection Agency, Office of Pesticide Program, Durham, NC, USA.

Elizabeth Mendez (E)

U.S. Environmental Protection Agency, Office of Pesticide Programs, Washington, DC, USA.

Michelle Embry (M)

Health and Environmental Sciences Institute, Washington, DC, USA. Electronic address: membry@hesiglobal.org.

Yu-Mei Tan (YM)

U.S. Environmental Protection Agency, Office of Pesticide Program, Durham, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH